Prs17 Comparison of Outpatient and Inpatient Costs of Moderate and Severe Exacerbations of Copd in Poland in 2007

Jahnz-Rózyk, K; Targowski, Tomasz; Mierzejewska, MJ; From, Sławomir

doi:10.1016/s1098-3015(10)66514-x

Cited by 2 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Jahnz-Rozyk et al [11] followed 73 patients, treated for exacerbations in hospital pulmonary departments or in ambulatory care in Poland, and analyzed the direct and indirect costs. The mean cost of an exacerbation was €1397, while indirect costs accounted for 14% of the total cost.…”

Section: Discussionmentioning

confidence: 99%

The Cost of COPD Exacerbations Managed in Hospital

Varol¹,

Varol²,

Başer³

et al. 2013

Tur Toraks Der

View full text Add to dashboard Cite

AmAç: Kronik Obstrüktif Akciğer Hastalığı (KOAH) belirgin sağlık ve ekonomik sonuçları olan ve sık görülen bir hastalıktır. Bu çalışmada, hastanemizde KOAH alevlenmesine bağlı yatış gerektiren hastaların maliyet analizi yapılmıştır. Gereç ve Yöntemler: Hastanemiz göğüs servisine, bir yıl boyunca, KOAH alevlenmesi nedeniyle yatışı yapılan 376 hastanın direk maliyet analizi değerlendirilmiştir. BulGulAr: Çalışmaya alınan hastaların 311'i erkek, 65 tanesi kadındır. Hastaların median yatış süresi 8 (ortalama: 9.86) gündür ve ortalama yaşı 65.31'dir. Her atak başına düşen ilaç maliyeti 526.55 Türk Lirası (TL) ($392.94, €333.25), hastane bakım maliyeti 1271.94 TL ($949.20, €805.02) ve genel maliyet 1833.8537 TL'dır ($1368.54, €1160.66). Akciğer kanseri ve sekel akciğer tüberkülozu ek hastalığı olan hastalarda hastane yatış süresi istatistiksel olarak daha uzundur. Antibiyotik kullanımı hastane yatış süresini ve maliyeti arttırmıştır. Yoğun bakımda tedavi görülmesi, hastane kökenli enfeksiyon varlığı ve uzun süreli oksijen ihtiyacı maliyeti ve hastane yatış süresini arttırmıştır. Sonuç: Bu çalışmada, hastane yatışı gerektiren KOAH alevlenmelerinde antibiyotik kullanımının, hastane kökenli enfeksiyon varlığının, uzun süreli oksijen tedavisinin ve yoğun bakımda tedavi görülmesinin maliyeti arttırdığı saptanmıştır. AnAhtAr Sözcükler: KOAH, alevlenme, maliyet Geliş Tarihi: 12.02.2011 Kabul Tarihi: 06.09.2011 oBJectIveS: Chronic obstructive pulmonary disease (COPD) is a common disease that has severe health and economic consequences. In this study we estimated the economic cost of COPD exacerbations requiring hospital stay in our hospital. mAterIAl And methodS: The direct cost of 376 hospitalizations during one year with the diagnosis of COPD exacerbations were evaluated retrospectively in our hospital's chest diseases department. reSultS: Three hundred and eleven of the patients enrolled in the study were men while only 65 were women. The mean age of patients was 65.31 and median hospitalization time was 8 (mean: 9.86) days. The average medication cost per exacerbation was 526.55 Turkish Lira (TL) ($392.94, €333.25), the average hospital care cost per exacerbation was 1271.94 TL ($949.20, €805.02) and the average total cost per exacerbation was 1833.8537 TL ($1368.54, €1160.66). The hospitalization time for patients with lung malignancy and sequelae of lung tuberculosis were found to be statistically longer. Antibiotic treatment increased the costs and hospitalization time. Treatment in intensive care units, nosocomial infections and necessity of long term oxygen treatment all increased the costs and hospital stay time.concluSIon: This study shows that the cost of intensive care unit treatment, long term oxygen treatment, treatment of hospital acquried infections and use of antibiotics were higher than usual in COPD exacerbations requiring hospitalisations.

show abstract

Section: Discussionmentioning

confidence: 99%

The Cost of COPD Exacerbations Managed in Hospital

Varol¹,

Varol²,

Başer³

et al. 2013

Tur Toraks Der

View full text Add to dashboard Cite

show abstract

“…The most prevalent form of pneumococcal disease in older adults is community-acquired pneumonia (CAP), which presents a substantial clinical and economic burden (12−15). Moreover, S. pneumoniae is a major contributor to exacerbations of COPD (16), the disease burden in the Region is at least comparable to, and may even exceed, that of CAP (13,17). Therefore, the burden of pneumococcal disease in adults is immense.…”

Section: Pneumococcal Disease: a Major Preventable Health Burdenmentioning

confidence: 99%

Opportunity for Healthy Ageing: Lessening the Burden of Adult Pneumococcal Disease in Central and Eastern Europe, and Israel

Ludwig¹,

Ünal²,

Bogdan³

et al. 2012

Cent Eur J Public Health

View full text Add to dashboard Cite

SUMMARYThe population of the Region (Central Europe, Eastern Europe, and Israel) is ageing, necessitating preventative programmes to maintain a healthy and active lifestyle in older age groups. Invasive pneumococcal disease (including bacteremic pneumonia, bacteremia without a focus, and meningitis) has higher incidence, morbidity and mortality in older adults and is a substantial public health burden in the ageing population.Surveillance in the Region establishes a significant burden in older adults of invasive pneumococcal disease (IPD), which still appears to be under-estimated as compared with other countries, and this warrants an improvement in surveillance systems. The largest proportion of IPD in adults is bacteremic pneumonia. Community-acquired pneumonia (CAP), largely attributable to S. pneumoniae, can be bacteremic or non-bacteremic; the non-bacteremic forms of CAP also represent a significant burden in the Region.The burden of pneumococcal disease can be reduced with programmes of effective vaccination. Recommendations on pneumococcal vaccination in adults vary widely across the Region. The main barrier to implementation of vaccination programmes is low awareness among healthcare professionals on serious heatlh consequences of adult pneumococcal disease and of vaccination options.The Expert Panel calls on healthcare providers in the Region to improve pneumococcal surveillance, optimize and disseminate recommendations for adult vaccination, and support awareness and education programmes about adult pneumococcal disease. Healthy Ageing: a Growing Public Health IssueThe proportion of adults in the Region (Central Europe, Eastern Europe, and Israel) over the age of 50 years has nearly doubled in the past six decades (Fig. 1) and is forecasted to double again by 2040 (1). As a consequence, the Region will increasingly face the issue of "healthy ageing" (i.e. maintaining the general level of health, quality of life and active lifestyle in an ageing population).

show abstract

Prs17 Comparison of Outpatient and Inpatient Costs of Moderate and Severe Exacerbations of Copd in Poland in 2007

Cited by 2 publications

References 0 publications

The Cost of COPD Exacerbations Managed in Hospital

The Cost of COPD Exacerbations Managed in Hospital

Opportunity for Healthy Ageing: Lessening the Burden of Adult Pneumococcal Disease in Central and Eastern Europe, and Israel

Contact Info

Product

Resources

About